National Cardiovascular Disease Database (NCVD) NCVD Acute Coronary Syndrome (ACS) Registry An Update Dato’ Dr Azhari Rosman Chairman of NCVD ACS Registry.

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

The Macstrak Project CCU Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
Risk stratification and medical management of NSTE-ACS (UA/NSTEMI )
ECG interpretation for beginners Part 4 – Acute coronary syndromes
Ischaemic Heart Disease- Implications of Gender Dr Kaye Birks School of Rural Health Monash University Australia Gender Competency Training for Medical.
The Macstrak Project CCU Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
NCVD-ACS REGISTRY. Annual Report of the Acute Coronary Syndrome (ACS) Registry, Malaysia 2006 NCVD-ACS Registry: Annual Report 2006 Published by: Clinical.
National Cardiovascular Disease Database (NCVD) 2009 Update NHAM ASM April 2009 National Cardiovascular Disease Database (NCVD) ACS Registry PCI.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Cardiovascular Care in Malaysia: Role of NCVD
National Cardiovascular Disease Database Percutaneous Coronary Intervention (PCI) Registry Malaysia NCVD-PCI Registry – Are We Any Different? Presented.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Chest Pain Dr. Shamim Nassrally BSc (Hons) MB ChB MRCP(UK)
Scenario 1Scenario 1  58 year old man  30 minute history of severe chest pain, 10/10, radiating to jaw, not relieved by anything, associated with sweating.
NCVD Percutaneous Coronary Intervention (PCI) Registry An update Dato Dr Rosli Mohd Ali Chairman of NCVD PCI Registry Hilton Kuala Lumpur 17 th April 2009.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
‘Taxi Driver in Pain’ Tiara Gill Carrie Ross Mark Hambly.
Indication and contra-indications for cardiac catheterization
Chest Pain Dr. Shamim Nassrally BSc (Hons) MB ChB MRCP(London) Clinical Teaching Fellow.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
DR. ZAHOOR 1.  A 50 year old man presents to clinic with a complaint of central chest discomfort of 2 weeks’ duration, occurring after walking for more.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Acute Coronary Syndrome
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Update of 2013 ACCF/AHA Guidelines for STEMI Junbo Ge MD,FACC,FESC,FSCAI Zhongshan Hospital, Fudan University.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Acute Coronary Syndromes in West Hertfordshire Masood Khan.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Dr AM Thirugnanam, Senior Interventional Cardiologist, Follow me on Face book, Twitter, Youtube Ipcard Cardiac Care Center, Hyderabad, Date:15/07/2013.
Acute Coronary Syndrome
The OPTImal CArdiac REhabilitation (OPTICARE) trial:
Cardiology Division, Jeju National University Hospital, Jeju, KOREA
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Baseline characteristics and effectiveness results
CORONARY ARTERY DISEASE
Gender differences in the management of acute coronary syndrome patients: One year results from HPIAR (HP-India ACS Registry) Kunal Mahajan*, Negi PC,
10 Year Experience with the Malaysian ACS & PCI Registries:
Summary of the Annual Report of the NCVD-ACS Registry
Ischaemic Heart Disease Acute Coronary Syndrome
The Anglo Scandinavian Cardiac Outcomes Trial
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
NCVD Acute Coronary Syndrome (ACS) Registry An Update Dato’ Dr Azhari Rosman Chairman of NCVD ACS Registry Sentral Accord Room, Hilton Kuala Lumpur 19th.
Statins Evaluation in Coronary procedUres and REvascularization
European Heart Association Journal 2007 April
Volume 93, Issue 4, Pages (April 2018)
Orlando, March , American College of Cardiology
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
What oral antiplatelet therapy would you choose?
Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome  Jonas Faxén, Hong Xu,
NCVD-ACS REGISTRY.
Atlantic Cardiovascular Patient Outcomes Research Team
MRRs and EMRRs for women with ACS
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

National Cardiovascular Disease Database (NCVD) NCVD Acute Coronary Syndrome (ACS) Registry An Update Dato’ Dr Azhari Rosman Chairman of NCVD ACS Registry Sentral Accord Room, Hilton Kuala Lumpur 19 th April 2009

National Cardiovascular Disease Database (NCVD) *SGH *HSAJB *PH HSJ *IJN *UMMC *HKL *HTAR ACS Registry Participating Sites *QEH * Active sites *HI HSNZ *HRPZ II*HTF *HSB *HTJ *HTAA *HM MMC (2009)

National Cardiovascular Disease Database (NCVD) 1. Report: NCVD-ACS Registry Annual report year 2006 Downloadable online at Current Activities

National Cardiovascular Disease Database (NCVD) 2. NCVD-ACS Registry Annual Report year 2007 Currently in the midst of data- cleaning stage Current Activities

National Cardiovascular Disease Database (NCVD) Current Updates as of 9 th April 2009 (based on unclean data)

National Cardiovascular Disease Database (NCVD) Acute Coronary Syndrome (ACS) Registry

National Cardiovascular Disease Database (NCVD) ACS cases registered online by Source Data Providers (SDP) Results as of 9 th April 2009, n= 10,864 Total SDP = 15 sites

National Cardiovascular Disease Database (NCVD) Patient’s Demographics Age Min, Max mean + sd 18.33, yrs yrs Male75.31 % Ethnic : Malay47.47 % Chinese22.96 % Indians23.25 % Other Malaysian3.88 % Foreigner1.33 % * Other Malaysians include Punjabi, Iban, Kadazan Dusun, Orang Asli, Melanau, Murut, Bajau, Bidayuh ** For 121 cases, there are no information on ethnicity Baseline (n= 10,730) Baseline (n= 10,864)

National Cardiovascular Disease Database (NCVD) Smoking Status Never36.25 % Stopped (quit > 30 days)21.45 % Current (within last 30 days)32.03 % Not Available10.27 % Status of Aspirin use Used <7 days10.47 % Used >7 days22.06 % None51.96 % Unknown15.51 % Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) CV Risk Factors Dyslipidaemia32.42 % Hypertension57.69 % Diabetes40.56 % Family History of premature CVD11.16 % MI history16.68 % Documented CAD16.21 % New onset angina (< 2 weeks)48.08% Chronic angina (onset > 2 weeks ago)11.29% Chronic Lung Disease3.26 % Renal disease6.40 % Peripheral vascular disease0.75 % Cerebrovascular disease3.42 % Heart Failure6.46 % Results as of 9 th April 2009, n= 10,864

Institut Jantung Negara National Heart Institute Risk Factors: Malaysian NCVD-PCI Registry(IJN) 51% 72% 82%

National Cardiovascular Disease Database (NCVD) No episode14.42 % % % % % % % % Number of distinct angina episode within 24hrs % % % % % % NA37.48 % Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Heart Rate83.5 beats/min Systolic BP mmHg Diastolic BP81.12 mmHg Clinical Examination Killip classification I46.27 % II16.37 % III3.94 % IV3.31 % Not stated/inadequately described12.73 % Not available17.38 % Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) ECG abnormalities type ST-segment elevation ≥ 1mm (0.1mV) in ≥ 2 contiguous limb leads % ST-segment elevation ≥ 2mm (0.2mV) in ≥ 2 contiguous frontal leads or chest leads % ST-segment depression ≥ 0.5mm (0.05mV) in ≥ 2 contiguous leads % T-wave inversion ≥ 1mm (0.1mV) % Bundle branch block (BBB) 4.95 % Non-specific 5.23 % None 6.01 % Not stated / inadequately described 1.86 % Baseline (n= 10,864) Results as of 9 th April 2009

National Cardiovascular Disease Database (NCVD) ECG abnormalities location Inferior leads : II, III, aVF31.42 % Anterior leads : V1 to V % Lateral leads : I, aVL, V5 to V % True posterior : V1 V24.58 % Right ventricle : ST elevation in lead V4R3.77 % None9.86 % Not stated / inadequately described3.89 % Baseline (n= 10,864) Results as of 9 th April 2009

National Cardiovascular Disease Database (NCVD) Percentage of Ischaemic status by ACS stratum (n=10,864) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Percentage according to TIMI Risk Score for STEMI (n= 4,705) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Percentage according to TIMI Risk Score for NSTEMI/UA (n=5,427) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Given at this centre % Given at another centre prior to transfer % Not given - proceeded directly to primary angioplasty 7.25 % Not given - Missed Thrombolysis % Not given - patient refusal 0.17 % Not given - Contraindicated 4.21 % Not Applicable 2.67 % Fibrinolytic Therapy Status Baseline (n= 4,705) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Fibrinolytic Drug Used (n=2,861) Streptokinase91.68 % Others2.31 % Missing6.01 % Door to needle time (mins) Cardiac Cathetherization Yes19.00 % No60.73 % No - transferred to another centre2.31 % Missing17.95 % Baseline (n= 10,864) Results as of 9 th April 2009

National Cardiovascular Disease Database (NCVD) PCI on this admission Yes (n=1,588)14.62 % Yes – for STEMI42.1 % No55.56 % Not Applicable12.08 % Missing17.75 % Door to balloon time (mins) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Pharmacological Therapy Drug used/given during admission (%) Drug Pre- admission During After discharge ASA ADP Antagonist GP Receptor inhibitor Unfrac Heparin LMWH Beta Blocker ACE Inhibitor Angiotensin II receptor blocker Statin Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Drug used/given during admission (%) Drug Pre- admission During After discharge Other Lipid Lowering Agent Diuretics Calcium Antagonist Oral Hypoglycaemic Agent Insulin Anti-arrhythmic Agent Results as of 9 th April 2009, n= 10,864 Pharmacological Therapy

National Cardiovascular Disease Database (NCVD) In-hospital Clinical Outcome Outcome (%) Discharged85.65 Transferred1.98 Died6.91 NA5.55 Cause of Death (%) CVD74.57 Non-CVD4.39 Other2.26 Missing18.77 Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) In-hospital Clinical Outcome Final Diagnosis at Discharge (%) Q Wave MI35.76 Non-Q Wave MI19.89 Unstable Angina24.96 Stable Angina1.20 Non-cardiac1.45 Missing Bleeding Complication (TIMI Criteria) (%) Major0.49 Minor1.58 Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Follow up at 30days & 1year

National Cardiovascular Disease Database (NCVD) Overall Follow Up Management Type of FU30days FU1year FU TotalN%N% Expected visits FU Done Missed FU Results as of 9 th April 2009

National Cardiovascular Disease Database (NCVD) Overall Follow Up done at 30days & 1year

National Cardiovascular Disease Database (NCVD) Follow Up done at 30days & 1year by SDP Percentage of FU done (%) SDP Total 30days FU = 6,493 (as of 9 th April 2009) Total 1year FU = 3,352 (as of 9 th April 2009)

National Cardiovascular Disease Database (NCVD) Cardiovascular readmission ACS STEMI NSTEMI UA Missing 3.89 % % % % % Heart Failure0.49 % Revascularization5.15 % PCI87.54 % CABG9.79 % Stroke0.11 % 2.07 % % 7.14 % % % 0.53% 3.11% % % 0.06 % 30days (n= 6,550)1year (n= 3,374) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Outcome at 30 days & 12 months % 3.45 % 8.98 % 0.58 % 1.6 % Outcome Alive Death Lost to FU Transferred Missing % 2.31 % % 0.18 % 2.4 % Cause of Death CVD Non CVD Others Missing % 8.97 % % % 1year (n= 3,374) 1year (n= 78) 30days (n= 6,550) % % % % 30days (n= 226) Results as of 9 th April 2009, n= 10,864

National Cardiovascular Disease Database (NCVD) Thank you